戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 2 receptor currently under investigation for hereditary angioedema.
2 term prophylactic and on-demand treatment in hereditary angioedema.
3 that supports potential prophylactic use for hereditary angioedema.
4  FDA-approved drug to treat acute attacks of hereditary angioedema.
5 e on-demand therapy for all individuals with hereditary angioedema.
6 al plasma kallikrein levels in patients with hereditary angioedema.
7 istrations of garadacimab as prophylaxis for hereditary angioedema.
8 ds complete disease control of patients with hereditary angioedema.
9 d safety data for garadacimab in adults with hereditary angioedema.
10 the first patient to be potentially cured of hereditary angioedema.
11 bant is approved for treatment of attacks of hereditary angioedema.
12 culation, and to treat the swelling disorder hereditary angioedema.
13 1 inhibitor concentrate in the management of hereditary angioedema.
14 wed interest in the biology and treatment of hereditary angioedema.
15 ms, the pathophysiology and the treatment of hereditary angioedema.
16 r C1 inhibitor (C1INH) deficiency results in hereditary angioedema.
17 enously every third day to six patients with hereditary angioedema.
18 n the prevention and treatment of attacks of hereditary angioedema.
19 occurring mutant from a patient with type II hereditary angioedema.
20  65 eligible patients with type I or type II hereditary angioedema, 39 were randomly assigned to gara
21 unction mutations in factor XII (FXII) cause hereditary angioedema, a life-threatening tissue swellin
22 or establishing "A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency,
23 nts (aged >=12 years) with type I or type II hereditary angioedema across seven countries (Canada, Ge
24                                         Like hereditary angioedema, acute IRI is also related to the
25  phase 2 trial, individuals with type 1 or 2 hereditary angioedema aged 18 years or older were recrui
26  conducted in patients with acute attacks of hereditary angioedema and assessed the length of time to
27          It is a key player in some types of hereditary angioedema and is involved in septic shock, t
28         An infant with genetically confirmed hereditary angioedema and low C1 inhibitor levels (but w
29 ffective means of both preventing attacks of hereditary angioedema and treating acute attacks.
30                                   Attacks of hereditary angioedema are attributed to excessive plasma
31                          Nearly all cases of hereditary angioedema are caused by mutations in the gen
32                              In 2013, the US Hereditary Angioedema Association guidelines recommended
33                                              Hereditary angioedema attack history was collected at sc
34           Donidalorsen treatment reduced the hereditary angioedema attack rate, a finding that suppor
35 estigator-assessed time-normalised number of hereditary angioedema attacks (number of hereditary angi
36 s, guidelines for the on-demand treatment of hereditary angioedema attacks have undergone significant
37 ity of the pathomechanism and development of hereditary angioedema attacks in different patients.
38 dacimab administration significantly reduced hereditary angioedema attacks in patients aged 12 years
39 gible if they had experienced at least three hereditary angioedema attacks in the past 93 days, were
40            Approved on-demand treatments for hereditary angioedema attacks need to be administered pa
41 -normalized number of investigator-confirmed hereditary angioedema attacks per 4 weeks (attack rate)
42                         The median number of hereditary angioedema attacks per month was 0 (IQR 0.00-
43 ), the mean number of investigator-confirmed hereditary angioedema attacks per month was significantl
44  of hereditary angioedema attacks (number of hereditary angioedema attacks per month) during the 6-mo
45 ma kallikrein inhibitor developed to prevent hereditary angioedema attacks.
46 IIa), is being studied for the prevention of hereditary angioedema attacks.
47 s in development, for on-demand treatment of hereditary angioedema attacks.
48  mediator-induced), ACE-inhibitor intake and hereditary angioedema (both bradykinin-mediated).
49 HK, as was seen in plasma from patients with hereditary angioedema but not plasma from healthy subjec
50 C1INH is effective not only in patients with hereditary angioedema, but also in a variety of other di
51 ource for plasmin generation in all types of hereditary angioedema, but particularly hereditary angio
52                           Because attacks of hereditary angioedema can be related to infection and/or
53 gic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency
54                      More than 500 different hereditary angioedema-causing variants have been identif
55                          Among patients with hereditary angioedema, donidalorsen treatment resulted i
56                                              Hereditary angioedema due to C1 inhibitor deficiency (HA
57                                              Hereditary angioedema due to C1 inhibitor deficiency is
58  the heterogeneous clinical manifestation of hereditary angioedema due to C1-INH deficiency (C1-INH-H
59 ited edematous attack (EA) in a patient with hereditary angioedema due to C1-INH deficiency to better
60 zyme systems is insufficiently controlled in hereditary angioedema due to the deficiency of C1-inhibi
61                                Patients with hereditary angioedema experience recurrent, sometimes li
62 Plasma-derived C1-INH has been used to treat hereditary angioedema for more than 30 years with excell
63 adykinin-mediated angioedema, which includes hereditary angioedema (HAE types I, II and III), acquire
64 ety of lanadelumab in patients 12 y old with hereditary angioedema (HAE) 1/2 (NCT02741596).
65 y of lanadelumab in patients >=12 y old with hereditary angioedema (HAE) 1/2 (NCT02741596).
66 he serpin C1-inhibitor, but individuals with hereditary angioedema (HAE) are deficient in C1-inhibito
67                         Approximately 85% of hereditary angioedema (HAE) attacks are associated with
68                                              Hereditary angioedema (HAE) attacks can be provoked with
69                  Historically, treatment for hereditary angioedema (HAE) attacks has been administere
70 adelumab demonstrated efficacy in preventing hereditary angioedema (HAE) attacks in the phase 3 HELP
71 ikrein in development for the prophylaxis of hereditary angioedema (HAE) attacks.
72 (2) receptor antagonist, in the treatment of hereditary angioedema (HAE) attacks.
73                                              Hereditary angioedema (HAE) caused by a deficiency of fu
74                                              Hereditary angioedema (HAE) caused by C1-inhibitor (C1-I
75                                              Hereditary angioedema (HAE) comprises HAE with C1-inhibi
76         Recommended management of attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor
77                                              Hereditary angioedema (HAE) due to C1 inhibitor deficien
78                                              Hereditary angioedema (HAE) due to C1-inhibitor deficien
79                                Patients with hereditary angioedema (HAE) experience episodes of brady
80                                Patients with hereditary angioedema (HAE) experience episodes of soft
81                                Patients with hereditary angioedema (HAE) have gained additional acces
82 ons in Factor XII (FXII) are associated with hereditary angioedema (HAE) in the presence of normal C1
83                                              Hereditary angioedema (HAE) is a disease characterized b
84                                              Hereditary angioedema (HAE) is a genetic disorder that m
85                                              Hereditary angioedema (HAE) is a heterozygous deficiency
86                                              Hereditary angioedema (HAE) is a potentially fatal disea
87                                              Hereditary angioedema (HAE) is a potentially fatal disor
88                                              Hereditary angioedema (HAE) is a rare and potentially li
89                                              Hereditary angioedema (HAE) is a rare disease characteri
90                                              Hereditary angioedema (HAE) is a rare genetic disease ch
91                                              Hereditary angioedema (HAE) is a rare genetic disease ch
92                                              Hereditary Angioedema (HAE) is a rare genetic disease ge
93                                              Hereditary angioedema (HAE) is a rare genetic disease th
94                                              Hereditary angioedema (HAE) is a rare genetic disease us
95                                              Hereditary angioedema (HAE) is a rare genetic disorder c
96                                              Hereditary angioedema (HAE) is a rare genetic disorder i
97                                              Hereditary angioedema (HAE) is a rare genetic disorder p
98                                              Hereditary angioedema (HAE) is an autosomal dominant dis
99                                              Hereditary angioedema (HAE) is an autosomal dominant inh
100                                              Hereditary angioedema (HAE) is associated with episodic
101                                              Hereditary angioedema (HAE) is associated with recurrent
102                                              Hereditary angioedema (HAE) is characterized by unpredic
103                                              Hereditary angioedema (HAE) types I and II were then tes
104 n established treatment for acute attacks of hereditary angioedema (HAE) with C1-inhibitor (C1-INH) d
105                                              Hereditary angioedema (HAE) with normal C1 inhibitor (C1
106                                              Hereditary angioedema (HAE) with normal C1 inhibitor (HA
107                                              Hereditary angioedema (HAE) with normal C1-INH (HAEnCI)
108      Deficiency of C1-INH is associated with hereditary angioedema (HAE), an autosomal inherited dise
109                             In patients with hereditary angioedema (HAE), bradykinin causes swelling
110                                              Hereditary angioedema (HAE), caused by C1 inhibitor prot
111                                              Hereditary angioedema (HAE), caused by deficiency in C1-
112 cation availability and improve diagnosis of hereditary angioedema (HAE), particularly in emerging ec
113 d update the management and understanding of hereditary angioedema (HAE), while integrating insights
114 bradykinin-mediated swelling disorder called hereditary angioedema (HAE).
115  in the understanding of the pathogenesis of hereditary angioedema (HAE).
116 inhibitor under development for treatment of hereditary angioedema (HAE).
117 codes FXII, provoke acute tissue swelling in hereditary angioedema (HAE).
118 ted quality of life (HRQoL) in patients with hereditary angioedema (HAE).
119 at in adolescent and adult participants with hereditary angioedema has been initiated (NCT05259917).
120  1-2 trial, we randomly assigned adults with hereditary angioedema in a 2:2:1 ratio to receive NTLA-2
121 al prophylactic therapy for the treatment of hereditary angioedema in adolescents and adults.
122                                              Hereditary angioedema is a disabling, potentially fatal
123                                              Hereditary angioedema is a potentially life-threatening
124                                              Hereditary angioedema is a potentially life-threatening
125                                              Hereditary angioedema is a rare and potentially life-thr
126                                              Hereditary angioedema is a rare disorder characterized b
127                                              Hereditary angioedema is a rare genetic disease characte
128                                              Hereditary angioedema is a rare genetic disease that lea
129                                              Hereditary angioedema is an autosomal-dominant deficienc
130                                              Hereditary angioedema is characterized by recurrent and
131                                              Hereditary angioedema is characterized by recurrent and
132                                              Hereditary angioedema is often misdiagnosed and poorly t
133 hibitor (rhC1INH) for on-demand treatment of hereditary angioedema is purified from milk of transgeni
134                             In patients with hereditary angioedema, kallikrein and bradykinin formati
135 with placebo, reduced the rate of attacks of hereditary angioedema (mean difference with 40 IU, -2.42
136                             In subjects with hereditary angioedema, nanofiltered C1 inhibitor concent
137 t factors which trigger and/or contribute to hereditary angioedema or ACE-inhibitor-mediated angioede
138                                     A type I hereditary angioedema patient was recently described in
139    In the autosomal dominant disorder type I hereditary angioedema, reduced levels of C1 inhibitor ma
140 ortance of the contact activation system for hereditary angioedema-related vascular permeability.
141                                              Hereditary angioedema results from a congenital deficien
142 a crossover trial involving 22 subjects with hereditary angioedema that compared prophylactic twice-w
143                             In patients with hereditary angioedema, the prophylactic use of a subcuta
144  randomized trial, we assigned patients with hereditary angioedema to receive donidalorsen (80 mg sub
145  least 12 years of age with type 1 or type 2 hereditary angioedema to take up to two oral doses of se
146                                              Hereditary angioedema type III (HAEIII) is a rare inheri
147  MeSH terms angioedema, acquired angioedema, hereditary angioedema type III, and angiotensin converti
148                                              Hereditary angioedema types I and II are caused by a fun
149 cimab for more than 2 years in patients with hereditary angioedema was well tolerated and efficacious
150  phase 1-2 trial of NTLA-2002 in adults with hereditary angioedema, we administered NTLA-2002 at a si
151 s aged 18-65 years with clinically confirmed hereditary angioedema were eligible.
152    Four types of acquired and three types of hereditary angioedema were identified as separate forms
153 tients with chronic spontaneous urticaria or hereditary angioedema were repeatedly asked to complete
154 terozygosity for C1INH deficiency results in hereditary angioedema, which is mediated by bradykinin.
155 us CSL830 in patients with type I or type II hereditary angioedema who had had four or more attacks i
156                                              Hereditary angioedema with a mutation in the PLG gene is
157 The consensus documents published to date on hereditary angioedema with C1 inhibitor deficiency (C1-I
158                                              Hereditary angioedema with C1 inhibitor deficiency (C1-I
159                                              Hereditary angioedema with C1 inhibitor deficiency is ch
160 ministration of lanadelumab to patients with hereditary angioedema with C1 inhibitor deficiency reduc
161 eight kininogen in plasma from patients with hereditary angioedema with C1 inhibitor deficiency to le
162 omly assigned, in a 2:1 ratio, patients with hereditary angioedema with C1 inhibitor deficiency to re
163                                Patients with hereditary angioedema with C1 inhibitor deficiency were
164  the potential for prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency.
165 gene variants, our data define some types of hereditary angioedema with C1INH deficiency as serpinopa
166                                              Hereditary angioedema with normal C1 esterase inhibitor
167                                              Hereditary angioedema with normal C1 inhibitor levels (H
168 s of hereditary angioedema, but particularly hereditary angioedema with normal C1 inhibitor with a fa
169                                              Hereditary angioedema with normal C1-INH may be linked t
170 hophysiology of the disease remains unknown (hereditary angioedema with yet unknown genetic defect [U

 
Page Top